← FDA DRUG APPROVALS

FDA ANDA · ANDA091594

GEMCITABINE HYDROCHLORIDE

Sponsor: ACCORD HLTHCARE

APPLICATION
ANDA091594
TYPE
ANDA
ORIGINAL APPROVAL
2011-07-25
LATEST ACTION
2024-09-24
ROUTE
INJECTION
DOSAGE FORM
INJECTABLE
MARKETING STATUS
Discontinued

Products

GEMCITABINE HYDROCHLORIDEDiscontinued
GEMCITABINE HYDROCHLORIDE EQ 1GM BASE/VIAL · INJECTABLE · INJECTION
GEMCITABINE HYDROCHLORIDEDiscontinued
GEMCITABINE HYDROCHLORIDE EQ 2GM BASE/VIAL · INJECTABLE · INJECTION
GEMCITABINE HYDROCHLORIDEDiscontinued
GEMCITABINE HYDROCHLORIDE EQ 200MG BASE/VIAL · INJECTABLE · INJECTION

Approval history

2024-09-24Labeling · Supplement 17 · standardAP
2024-09-24Labeling · Supplement 16 · standardAP
2019-10-17Labeling · Supplement 13 · standardAP
2019-10-17Labeling · Supplement 14 · standardAP
2019-10-17Labeling · Supplement 12 · standardAP
2015-06-02Labeling · Supplement 6 · standardAP
2015-06-02Labeling · Supplement 7 · standardAP
2011-09-06Labeling · Supplement 1AP
2011-07-25OriginalAP
VIEW ON DRUGS@FDA ↗

Related on SPEQ

Pharma industryGMP disciplineFDA drug shortagesFDA enforcement & recalls

Source: FDA Drugs@FDA. SPEQ is not affiliated with the FDA; this is a reference view of public FDA data, not medical, legal, or regulatory advice.

Weekly Briefing

Get the Weekly GxP Briefing

Curated regulatory intelligence — enforcement, recalls, guidance, and quality signals — in one practitioner-grade email each week. Free.

Read a past issue →